Stability of Antimalarial Preparations Rutendo Kuwana Accra, December 2009.
-
Upload
grant-baker -
Category
Documents
-
view
221 -
download
2
Transcript of Stability of Antimalarial Preparations Rutendo Kuwana Accra, December 2009.
Stability of Antimalarial Preparations
Rutendo Kuwana
Accra, December 2009
2 |
PQ: Artemisin-derivative issuesPQ: Artemisin-derivative issues
No innovator FPP registered in the ICH region. Therefore No
comparator available for:– Pharmaceutical equivalence studies– Bioequivalence studies
The APIs and FPPs not official in the internationally used major
pharmacopoeias
WHO guides/SOPs apply to multisource FPPs.
ICH guides therefore used
3 |
Expression of Interest – oral dosage formsExpression of Interest – oral dosage forms
Artesunate* + AmodiaquineArtemether* + Lumefantrine*Artesunate* + MefloquineArtesunate* + SP (sulphadoxine /
pyrimethamine)Dihydroartemisin+Piperaquine Phosphate** No comparator at the beginning * High quality-risk API+ ... FDC or co-blistered (co-packaged) FPPs* No comparator to date
4 |
EOI – other dosage formsEOI – other dosage forms
Artemether Injection and rectal FPPsArtemotil (arteether) InjectionArtesunate Injection and rectal FPPs
Only FPPs listed in the EOI will be discussed.
5 |
Availability of monographs for drug substances - International Pharmacopoeia
Availability of monographs for drug substances - International Pharmacopoeia
Artemether
Artemisinin
Artemotil
Artenimol
Artesunate
Mefloquine Hydrochloride
Proguanil Hydrochloride – Also in BP
Amodiaquine and Amodiaquine Hydrochloride – Also in USP
6 |
International quality standardsInternational quality standards
Lumefantrine Pyrimethamine BP, PhEur, PhInt, USP Sulphadoxine BP, PhEur, PhInt, USP Piperaquine Dihydroartemisinin
7 |
Other Antimalarial APIOther Antimalarial API
– APIs described in monographs of major international pharmacopoeias ( 10 years)• Chloroquine, Dapsone, Quinine, Mefloquine,
Trimethoprim– APIs not described in monographs of
major international pharmacopoeias• Chlorproguanil,, Naphthoquine, Pyronaridine
8 |
Properties of Artemisinin derivativesProperties of Artemisinin derivatives
Artemisinin (C15H22O5)– 7 centres of asymmetry– 27 potential isomers– One isomer in biosynthesis– Chemical synthesis
• Feasible• Economically unacceptable
Chemical derivatization at C-10 (carbonyl-moiety) converts C-10 into an additional stereoisomeric center:
• - and -isomers are formed
1
2
34
5
65a
8a7
8
910
1112
12a
9 |
ArtemisininArtemisinin
Active antimalarial constituent of the traditional Chinese
medicinal herb Artemisia annua L., Compositae
Although Artemisinin has seven (7) centers of assymetry
Artemisia annua makes only one configuration
Practically insoluble in water
The bond energy of the O-O bond is ~30 kcal/mol
When the peroxide comes into contact with high iron
concentrations, the molecule becomes unstable and
"explodes" into free radicals.
The API, the capsules and the tablets are official in the Ph.
Int. Not included in the current EOI.
10 |
ArtesunateArtesunate
Very slightly soluble in water
The ester linkage is in alpha configuration.
Both the API and the tablets are official in the Ph. Int.
Two functional groups are liable to decomposition
11 |
Metabolism of Artemether and ArtesunateMetabolism of Artemether and Artesunate
12 |
Mefloquine hydrochlorideMefloquine hydrochloride
Has an optically active carbon
Very slightly soluble in water
Has no reactive functional groups under general environmental conditions
13 |
Pharmaceutical informationPharmaceutical information
Artemisinin derivatives may have α- or β-configuration and each of them can exist in two conformations. The literature does not reveal any impact of the geometric isomerism on efficacy, safety or quality of artemisinins.
The internal peroxide bound is the most reactive part of the molecule. When the peroxide comes into contact with high iron concentrations, the molecule becomes unstable and "explodes" into free radicals.
The ester bond of artesunate is liable to hydrolysis.
The non-artemisinin APIs in the EoI are chemically stable.
14 |
Potential impurities of ArtemisininsPotential impurities of Artemisinins
Starting material (extracted from herbal sources)
Starting materials from vegetable origin should be fully characterized and a contaminant profile should be established
15 |
Potential impurities of Artemisinins IIPotential impurities of Artemisinins II
Impurities contained in the "starting material" Artemisinin– Biosynthetic by-products
• Arteannuin B , Artemisitene, Artemisinic acid,– Extraction from fresh leaves with CHCl3
• Thujone (?)
– Cultivation reagents• Pesticide residues, fumigants, mycotoxins
– Solvents from the extraction process• Hexane, benzene, acetonitril, ether, pentane, chloroforme…..(?) diesel, fuel (?)
[ICH Q3A (R)]
16 |
Potential impurities of Artemisinins IIIPotential impurities of Artemisinins III
Unreacted starting material– Artemisinin (starting material for derivatives)– Artemisinic acid (starting material for dihydroartemisinin)– Dihydroartemisinin (starting material for derivatives)– ….
Unreacted intermediates, by-products– -Arthemether, -Artheether– /-Dihydroartemisinin – -Artesunate
17 |
Potential impurities of Artemisinins IVPotential impurities of Artemisinins IV
Reagents, catalysts, residual solvents– Methanol, acetonitril, chloroforme, acetone …– NaBH4, succinic acid/anhydride, triethylamine, dimethylaminopyridine
Degradants– Stability of
• ester-derivative (Artesunate)• ether-derivative (Artemether, Arteether)• lactone (Artemisinin)
– Stability of artenimol (oxidation)– Susceptibility of endoperoxide bond to reduction
• Deoxyartemisinine (loss of active principle)
18 |
Compatibility of the API with excipients and diluents Compatibility of the API with excipients and diluents
Select innovator excipients (WHOPAR, EPAR)
Magnesium stearate is incompatible with salts of weak bases and strong acids (e.g. Amodiaquine.2HCl) because the formed MgCl2 is highly hygroscopic and, as a result, its lubricant properties also change.
The compatibility and in-use stability of the FPP with reconstitution diluents should be addressed, e.g. in Artesunate injection.
19 |
Increase in concentration of APIIncrease in concentration of API
During some stability studies of Artesunate, the assay results were increasing. The hydrolysis may yield artenimol and succinic acid. The latter can justify the increase in assay. The assay method may be considered to be "stability indicating” but not specific.
+
20 |
Stress TestingStress Testing
Artesunate
The drug substance degrades readily at heat conditions in extreme of 100ºC, it is also unstable under light conditions and both acid and base conditions by hydrolysis. The α-epimer of dihydroartemesinin is the major degradant under light conditions.
α-Artemether is the major degradant under heat conditions in extreme of 100ºC although both the α and ß epimers of dihydroartemesinin are also significant degradants under this condition.